Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
DUPRO steering committee and PROTECT Investigators
Research output: Contribution to journal › Article › peer-review
73Scopus
citations
Fingerprint
Dive into the research topics of 'Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial'. Together they form a unique fingerprint.